Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1574 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Labiotech.eu–Inova Software: investment, 202201 acquisition by Inova 2022-01-18
Amunix Pharmaceuticals–Sanofi: investment, 202112– acquisition $1b upfront + $225m milestones ANNOUNCED 2021-12-21
Argobio–GeneCode: GDNF mimetics, 202112– collab development with up to €3m funding for incubation phase by Argobio to incorporate new biotech company 2021-12-16
Depixus–Arix Bioscience: investment, 202112 financing round Series A totalling €30.6m incl existing + co-investor Arix Bioscience 2021-12-15
Depixus–Casdin Capital: investment, 202112 financing round Series A totalling €30.6m incl new + co-investor Casdin Capital 2021-12-15
Depixus–France (govt): investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor PSIM Fund managed by Bpifrence 2021-12-15
Depixus–Lansdowne Partners: investment, 202112 financing round Series A totalling €30.6m incl new + co-lead investor Lansdowne Partners 2021-12-15
Depixus–SEVERAL: investment, 202112 financing round Series A €30.6m co-led by Lansdowne Partners + PSIM Fund (Bpifrance) 2021-12-15
Corteria Pharmaceuticals–Invivo Capital: investment, 202112 seed financing round totalling €12m incl co-investor Invivo Capital 2021-12-09
Corteria Pharmaceuticals–Kurma: investment, 202112 seed financing round totalling €12m incl lead investor Kurma Partners 2021-12-09
Corteria Pharmaceuticals–NewCap: public relations, 202112 service existent by NewCap 2021-12-09
Corteria Pharmaceuticals–Omnes Capital: investment, 202112 seed financing round totalling €12m incl co-investor Omnes 2021-12-09
Corteria Pharmaceuticals–Sanofi: cardiovascular drugs, 202112c license to series of programs for heart failure drugs from Sanofi 2021-12-09
Corteria Pharmaceuticals–SEVERAL: investment, 202112 seed financing round €12m led by Kurma Partners 2021-12-09
Corteria Pharmaceuticals–V-Bio Ventures: investment, 202112 seed financing round totalling €12m incl co-investor V-Bio Ventures 2021-12-09
Emergence Therapeutics–SEVERAL: investment, 202112 financing round Series A €87m led by Pontifax Venture Capital 2021-12-07
HypnoVR–Andrew Lloyd Associates: public relations, 202112 service existent by ALA 2021-12-07
HypnoVR–SEVERAL: investment, 202112 financing round Series A €4.5m led by Theodorus 2021-12-07
HypnoVR–Theodorus: investment, 202112 financing round Series A totalling €4.5m incl new + lead investor Theodorus 2021-12-07
Integra Therapeutics–Advent France Biotechnology: investment, 202112 seed financing round totalling €4.5m incl investor Advent France Biotechnology 2021-12-02
Integra Therapeutics–SEVERAL: investment, 202112 seed financing round €4.5m with Advent FB + Invivo Capital + Takeda Ventures 2021-12-02
Origimm Biotechnology–Sanofi: investment, 202112– acquisition by Sanofi SIGNED 2021-12-01
EverImmune–SEVERAL: investment, 202111 financing round Series A €5m from undisclosed private investors 2021-11-30
HotSpot Therapeutics–SEVERAL: investment, 202111 financing round Series C $100m led by Pivotal BioVenture Partners 2021-11-29
HotSpot Therapeutics–Sofinnova: investment, 202111 financing round Series C totalling $100m incl existing + co-investor Sofinnova Partners 2021-11-29
Quell Therapeutics–SEVERAL: investment, 202111 financing round Series B $156m co-led by Jeito + Ridgeback Capital + SV Health Investors + Fidelity 2021-11-29
Owkin–Sanofi: investment, 202111 equity investment $180m by Sanofi in connection with strategic collaboration 2021-11-18
Sanofi–Owkin: cancer drug RnD, 202111– strategic collaboration with $90m for three years + milestones 2021-11-18
Synthace–SEVERAL: investment, 202111 financing round Series C $35m co-led by Sofinnova Partners + Horizon Ventures 2021-11-16
Synthace–Sofinnova: investment, 202111 financing round Series C totalling $35m incl existing + co-lead investor Sofinnova Partners 2021-11-16
Life Sciences Partners–EQT: investment, 202111– acquisition €450m upfront with €112.5m in cash + €337.5m in shares plus €25m milestone ANNOUNCED 2021-11-10
Home Biosciences–Redmile Group: investment, 202111 seed financing round totalling $15m incl co-lead investor Redmile Group 2021-11-09
Home Biosciences–SEVERAL: investment, 202111 seed financing round $15m led by Redmile Group + Sofinnova Partners 2021-11-09
Home Biosciences–Sofinnova: investment, 202111 seed financing round totalling $15m incl co-lead investor Sofinnova Partners 2021-11-09
PathoQuest–Aurinvest: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Aurinvest 2021-11-09
PathoQuest–Charles River: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Charles River Laboratories 2021-11-09
PathoQuest–Eurazeo: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Eurazeo 2021-11-09
PathoQuest–Kurma: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Kurma Partners 2021-11-09
PathoQuest–OTHER: investment, 202111 financing round Series B totalling up to €15m incl new + co-investor US Family Office 2021-11-09
PathoQuest–SEVERAL: investment, 202111 financing round Series B up to €15m led by new investor SHS Capital 2021-11-09
PathoQuest–SHS: investment, 202111 financing round Series B totalling up to €15m incl new + lead investor SHS Capital 2021-11-09
PathoQuest–Turenne Capital: investment, 202111 financing round Series B totalling up to €15m incl new + co-investor Turenne Capital/SHAM 2021-11-09
PathoQuest–Verve Capital Partners: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Verve Ventures 2021-11-09
GlycoEra–SEVERAL: investment, 202111 financing round Series A CHF45m co-led by 5AM Ventures + RVF + Sofinnova Partners 2021-11-05
GlycoEra–Sofinnova: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Sofinnova Partners 2021-11-05
Life Sciences Partners–SEVERAL: investment, 202111 announced LSP 7 fund with €850m incl EIF with expected final closing at €1b 2021-11-04
Bepatient–Alira Health: investment, 202110 acquisition of SAS Bepatient by Alira Health 2021-10-28
Sphere Fluidics–SEVERAL: investment, 202110 financing round $40m (c. £30m) co-led by Sofinnova Partners + Redmile Group 2021-10-28
Noxxon–LifeSci: public relations, 202110 service existent LifeSci Advisors is investor/media relations contact 2021-10-27
DNA Script–Agilent: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Agilent Technologies 2021-10-26
DNA Script–Alexandria Real Estate: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Alexandria VI 2021-10-26
DNA Script–ArrowMark Partners: investment, 202110 financing round Series C totalling $165m incl new + co-investor Arrowmark Partners 2021-10-26
DNA Script–Casdin Capital: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Casdin Capital 2021-10-26
DNA Script–Catalio Capital: investment, 202110 financing round Series C totalling $165m incl co-lead investor Catalio Capital Management 2021-10-26
DNA Script–Coatue Management: investment, 202110 financing round Series C totalling $165m incl co-lead investor Coatue Management 2021-10-26
DNA Script–Columbia Threadneedle: investment, 202110 financing round Series C totalling $165m incl new + co-investor Columbia Threadneedle Investments 2021-10-26
DNA Script–Danaher: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Danaher Life Sciences 2021-10-26
DNA Script–Farallon Capital: investment, 202110 financing round Series C totalling $165m incl new + co-investor Farallon Capital 2021-10-26
DNA Script–Fidelity: investment, 202110 financing round Series C totalling $165m incl new + co-investor Fideltiy Management and Research 2021-10-26
DNA Script–France (govt): investment, 202110 financing round Series C totalling $165m incl existing + co-investor Bpifrance Large Venture Fund 2021-10-26
DNA Script–Illumina: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Illumina Ventures 2021-10-26
DNA Script–Kurma: investment, 202110 financing round Series C totalling $165m incl existing + co-investor Kurma Partners 2021-10-26
DNA Script–Life Sciences Partners: investment, 202110 financing round Series C totalling $165m incl existing + co-investor LSP 2021-10-26
DNA Script–Merck (DE): investment, 202110 financing round Series C totalling $165m incl existing + co-investor M Ventures 2021-10-26
DNA Script–Moore Strategic Ventures: investment, 202110 financing round Series C totalling $165m incl new + co-investor Moore Strategic Ventures 2021-10-26
DNA Script–Seismic Marketing: public relations, 202110 service existent PR US by Seismic 2021-10-26
DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management 2021-10-26
Exciva–Andera Partners: investment, 202110 financing round Series A totalling €9m incl lead investor Andera Partners 2021-10-26
Exciva–SEVERAL: investment, 202110 financing round Series A €9m led by Andera Partners 2021-10-26
Valneva–SEVERAL: investment, 202110 private placement €76m of ordinary shares) at €17/share outside of US 2021-10-26
Valneva–SEVERAL: investment, 202110 public offering $653k+$13.3m of ADSs (each 2 ordinary shares) at $39.42/ADS in US 2021-10-26
Egle Therapeutics–SEVERAL: investment, 202110 financing round Series A €40m co-led by LSP + InnoBio 2 Fund of Bpifrance 2021-10-22
Leucid Bio–SEVERAL: investment, 202110 financing round Series A £11.5m led by Epidarex + Vulpes Investment Management 2021-10-21
Leucid Bio–Sofinnova: investment, 202110 financing round Series A totalling £11.5m incl existing + co-investor Sofinnova Partners 2021-10-21
Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners 2021-10-14
SparingVision–Intellia Therapeutics: CRISPR technology, 202110– collab incl license to use CRISPR/Cas9 to develop genomic ocular disease treatments 2021-10-13
SparingVision–Intellia Therapeutics: investment, 202110 Intellia receives 10% equity ownership in SparingVision as part of collab/license agreem 2021-10-13
CinCor Pharma–General Atlantic: investment, 202110 financing round Series B totalling $143m incl lead investor General Atlantic 2021-10-12
CinCor Pharma–SEVERAL: investment, 202110 financing round Series B $143m led by General Atlantic 2021-10-12
CinCor Pharma–Sofinnova: investment, 202110 financing round Series B totalling $143m incl existing + co-investor Sofinnova Partners 2021-10-12
iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG 2021-10-05
Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers 2021-10-04
Aglaia Therapeutics–Advent France Biotechnology: investment, 202109 seed financing round totalling €4m incl co-founder + lead investor AFB 2021-09-27
Aglaia Therapeutics–Crédit Mutuel-CIC: investment, 202109 seed financing round totalling €4m incl co-investor Crédit Mutuel Innovation 2021-09-27
Aglaia Therapeutics–Pierre Fabre: investment, 202109 seed financing round totalling €4m incl co-investor Pierre Fabre 2021-09-27
Aglaia Therapeutics–SEVERAL: investment, 202109 seed financing round €4m led by Advent FB with Crédit Mutuel Innovation + Pierre Fabre 2021-09-27
Jeito Capital–SEVERAL: investment, 202109 final closing Jeito I with addit €284m at €534m after €200m 1st close + €50m from Sanofi 2021-09-20
Clean Biologics–Andrew Lloyd Associates: public relations, 202109 service existent for Clean Cells by ALA 2021-09-15
Clean Biologics–ArchiMed: investment, 202109 investment existent by ArchiMed 2021-09-15
TreeFrog Therapeutics–BMS: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor BMS 2021-09-13
TreeFrog Therapeutics–France (govt): investment, 202109 financing round Series B totalling $75m (€64m) incl lead investor Bpifrance Large Venture 2021-09-13
TreeFrog Therapeutics–Leonard Green: investment, 202109 financing round Series B totalling $75m (€64m) incl co-investor Leonard Green + Partners LP 2021-09-13
TreeFrog Therapeutics–SEVERAL: investment, 202109 financing round Series B $75m (€64m) led by Bpifrance Large Venture 2021-09-13
TreeFrog Therapeutics–Siparex: investment, 202109 financing round Series B totalling $75m (€64m) incl exisiting + co-investor XAnge 2021-09-13
Oviva–SEVERAL: investment, 202109 financing round Series C $80m co-led by Sofina + Temasek 2021-09-01
Tissium–Cathay Capital: investment, 202108 financing round Series C totalling €50m incl new + co-lead investor Cathay Health 2021-08-31
Tissium–SEVERAL: investment, 202108 financing round Series C €50m co-led by Cathay Health + Sofinnova Partners 2021-08-31
Tissium–Sofinnova: investment, 202108 financing round Series C totalling €50m incl existing + co-lead investor Sofinnova Partners 2021-08-31
Afyren–SEVERAL: investment, 202108– IPO at Euronext Growth Paris registration document filed 2021-08-25
Translate Bio–Sanofi: investment, 202108– cash tender offer $3.2b at $38/share 2021-08-03
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16  next pagenext page



Advertisement

Picture Kentro Design Is Key to Your Success Berlin 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

» top